Stocksigma LogoStocksigma Logo

AstraZeneca Pharma India Receives Independent ESG Rating of 64 from Crisil for FY26

On 2nd Sep'26, AstraZeneca Pharma India disclosed receiving an ESG rating of 64 from Crisil ESG Ratings for FY26

AstraZeneca Pharma India Receives Independent ESG Rating of 64 from Crisil for FY26

AstraZeneca Pharma India Ltd 路 Others (Uncategorized) 路 02 Sept 2026, 11:45 pm

AstraZeneca Pharma India Receives Independent ESG Rating of 64 from Crisil for FY26 On 2nd Sep'26, AstraZeneca Pharma India disclosed receiving an ESG rating of 64 from Crisil ESG Ratings for FY26. The assessment was conducted independently based solely on publicly available information. Management clarified that the company did not formally engage Crisil for this evaluation, emphasizing the unsolicited nature of the ESG rating assignment.

Original exchange filing (PDF)

More announcements from AstraZeneca Pharma India Ltd

All AstraZeneca Pharma India Ltd announcements